Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
about
Incretin therapy--present and future.Deletion of GαZ protein protects against diet-induced glucose intolerance via expansion of β-cell massA retrospective audit of type 2 diabetes patients prescribed liraglutide in real-life clinical practice.Review of the safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.The cardiovascular safety of incretin-based therapies: a review of the evidence.Obviating much of the need for insulin therapy in type 2 diabetes mellitus: A re-assessment of insulin therapy's safety profile.Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes.
P2860
Q35760283-B7237349-D363-44F9-9463-DE006E29A6B8Q36016914-0C99C3DC-9DA6-4EE7-80BE-95B55FE56C60Q36941700-D0D7953A-41F8-4890-BABA-C77E4C9E5814Q37890793-BA185BC2-7221-4ADB-B9F6-B1B960A219A4Q38134902-FF2B2AD9-5168-4825-A269-7135CC76374CQ38841043-44B40F97-61DB-47C5-8F5B-4655FA95BC15Q51322701-6E90FEC7-51D6-4CF5-BC25-C1C44D694799
P2860
Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
@en
Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
@nl
type
label
Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
@en
Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
@nl
prefLabel
Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
@en
Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
@nl
P2860
P356
P1476
Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
@en
P2093
Paul S Jellinger
P2860
P356
10.3810/PGM.2011.01.2245
P407
P577
2011-01-01T00:00:00Z